Evidence map›Paper›PMID 42267299›Full record

ReviewFrontiers in endocrinology2026

Permanent hypoparathyroidism following SARS-CoV-2 infection: a case report with two-year follow-up and literature review.

Yizhi Zu, Hang Wang, Jinlin Wu, Cai Tang, Rui Han, Fang Fang

Abstract readCase ReportsReview
In one paragraph

Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yizhi Zu *Department of Endocrinology and Metabolism, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China.
Hang Wang *Department of Endocrinology and Metabolism, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China.
Jinlin WuDepartment of Endocrinology and Metabolism, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China.
Cai TangDepartment of Endocrinology and Metabolism, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China.
Rui HanDepartment of Endocrinology and Metabolism, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China.
Fang FangDepartment of Endocrinology and Metabolism, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Beyond its predominant respiratory involvement, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has also been implicated in endocrine dysfunction. Hypocalcemia is common in Coronavirus Disease 2019 (COVID-19), yet the insufficient compensatory rise in parathyroid hormone (PTH) and its long-term outcomes remain poorly characterized. We describe a young adult Chinese woman with no history of neck surgery who developed severe symptomatic hypocalcemia shortly after acute SARS-CoV-2 infection. Laboratory evaluation revealed inappropriately low PTH levels with concomitant hyperphosphatemia, consistent with hypoparathyroidism (HypoPT). Although baseline calcium/PTH data prior to infection were unavailable, the regular calcium and vitamin D supplementation, along with serial monitoring over more than two years, demonstrated persistently suppressed PTH secretion, supporting a diagnosis of permanent HypoPT. Thyroid imaging and antibody testing confirmed coexistent Hashimoto's thyroiditis, raising the possibility of an autoimmune contribution. To contextualize this case, we reviewed 14 previously published reports of COVID-19-associated HypoPT, among which no cases originating from China were identified. Based on available data, it cannot be ruled out that SARS-CoV-2 infection may contribute to the development of new-onset HypoPT in addition to worsening pre-existing conditions. Young-onset patients without a history of surgery-particularly those whose hypocalcemia severity does not clearly parallel the severity of infection-appear to have a higher likelihood of subsequent persistent dysfunction, though this observation remains preliminary. This case, together with the literature, underscores the need for extended follow-up in patients presenting with hypocalcemia and blunted PTH responses after COVID-19. Comprehensive autoimmune evaluation and, where appropriate, genetic testing should be considered to clarify etiology and guide long-term management.

Indexed as

COVID-19HypoparathyroidismAdultCalciumFemaleFollow-Up StudiesHashimoto DiseaseHumansHypocalcemiaPandemicsParathyroid HormonePost-Acute COVID-19 SyndromeSARS-CoV-2CalciumParathyroid HormoneautoimmuneHashimoto’s thyroiditishypocalcemiahypoparathyroidismSARS-CoV-2

Identifiers

PMID42267299
PMCPMC13243224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.